Acquire independent pharmacies, layer in specialty and compounding services, and create a defensible platform that commands premium multiples from PE buyers.
Find Pharmacy Platform TargetsThe independent pharmacy sector — roughly 19,000 locations generating $90B annually — is highly fragmented and ripe for consolidation. Retiring pharmacist-owners facing PBM reimbursement pressure are motivated sellers, creating a consistent deal pipeline for disciplined acquirers seeking to build scaled, multi-location platforms with differentiated specialty capabilities.
PBM compression squeezes single-location operators but rewards scaled platforms with negotiating leverage. Roll-ups spread fixed compliance and administrative costs, enable specialty and compounding cross-sell, and attract institutional capital at 5–7x EBITDA versus 3–4x for standalone independents.
Revenue of $2M–$5M with 10%+ EBITDA
Sufficient cash flow to support SBA or institutional financing, fund integration costs, and sustain operations during the ownership transition without requiring immediate operational overhaul.
Specialty, compounding, or LTC contract revenue
Non-PBM revenue streams such as compounding, long-term care, or hospice contracts provide margin insulation and a differentiated service base to build the platform identity around.
Licensed pharmacist willing to remain post-close
A retained, credentialed pharmacist ensures DEA and state board continuity, reduces patient attrition risk, and provides operational stability during platform buildout and add-on integrations.
Clean DEA and state board compliance record
No outstanding violations, audit findings, or payer credentialing issues that would complicate change-of-ownership approvals, delay licensing transfers, or introduce liability into the platform.
Active patient base with strong 30-day refill rates
Recurring prescription volume from loyal patients with high refill adherence translates directly into predictable revenue and supports earnout structures tied to patient file retention.
Geographic proximity to platform location
Add-ons within 20–50 miles enable shared pharmacist staffing, centralized inventory purchasing, and consolidated back-office operations that immediately improve combined EBITDA margins.
Revenue under $2M with motivated retiring owner
Smaller pharmacies owned by retiring pharmacists are priced at lower multiples and offer strong prescription file value relative to purchase price, accelerating returns within the roll-up.
No significant PBM audit exposure or DIR fee disputes
Add-ons with unresolved PBM clawbacks or DIR fee liabilities introduce unpredictable post-close adjustments that erode deal economics and complicate platform-level financial reporting.
Build your Pharmacy roll-up
DealFlow OS surfaces off-market Pharmacy targets with seller signals — the foundation of every successful roll-up.
Centralized purchasing and inventory management
Consolidating pharmaceutical purchasing across locations unlocks volume discounts from wholesalers like McKesson or AmerisourceBergen, directly improving gross margins across the entire platform.
Specialty and compounding service expansion
Layering compounding or specialty dispensing into retail-only add-ons generates higher-margin revenue outside standard PBM reimbursement, improving platform EBITDA and reducing reimbursement concentration risk.
Shared licensed pharmacist and technician staffing
Multi-location platforms can optimize pharmacist scheduling across sites, reducing overtime costs and improving coverage without proportionally increasing labor expense as the platform scales.
Unified PBM contract renegotiation
A scaled multi-location platform gains meaningful leverage to renegotiate PBM reimbursement rates and preferred network terms that individual independent pharmacies cannot access on their own.
A 4–6 location pharmacy platform generating $1.5M–$3M in EBITDA with specialty or LTC revenue is an attractive acquisition target for PE-backed healthcare services platforms or regional chain operators at 5–7x EBITDA, representing a 2–3 turn multiple expansion over individual pharmacy entry prices of 3–4x.
Most PE-backed healthcare platforms look for 4–6 locations with $1.5M+ in combined EBITDA and at least one differentiated service such as compounding, LTC contracts, or specialty dispensing before engaging seriously.
Each acquisition requires a separate DEA change-of-ownership application and state board approval. Plan 60–120 days per transaction and engage pharmacy-specialized legal counsel to manage concurrent regulatory timelines across add-ons.
SBA 7(a) loans support individual pharmacy acquisitions up to $5M, but scaling a roll-up typically requires transitioning to conventional or PE-backed financing after the platform location is established and cash flow is documented.
Patient and prescription volume attrition post-close is the primary risk. Mitigate it by retaining the selling pharmacist for 12–24 months, communicating proactively with patients, and structuring earnouts tied to refill rate retention.
More Pharmacy Guides
DealFlow OS surfaces off-market platform targets with seller motivation scores. Free to join.
Find platform targets — freeNo credit card required
For Buyers
For Sellers